Rhinovirus Real-Time Reverse-Transcription Polymerase Chain Reaction Assay —

Background—Rhinoviruses (RVs) are ubiquitous respiratory pathogens that often cause mild or subclinical infections. Molecular detection of RVs from the upper respiratory tract can be prolonged, complicating etiologic association in persons with severe lower respiratory tract infections. Little is known about RV viremia and its value as a diagnostic indicator in persons hospitalized with community-acquired pneumonia (CAP). Correspondence: X. Lu, MS, Division of Viral Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS G04, Atlanta, GA 30329 (xal9@cdc.gov). †Deceased. Presented in part: Sixth International Meeting on Emerging Diseases and Surveillance, Vienna, Austria, November 2016. Poster number: 20.016. Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Potential conflicts of interest. All reported support was received outside of the submitted work. W. H. S. reports grants from BioMerieux, Affinium Pharmaceuticals, Astute Medical, BRAHMS GmbH/Thermo Fisher, Pfizer, Rapid Pathogen Screening, Venaxis, BioAegis Inc, Sphingotec GmbH, and Ferring Pharmaceuticals, and personal fees from BioFire Diagnostics, Venaxis, Abbott Point of Care, and Cempra Pharmaceuticals. E. J. A. reports personal fees from AbbVie, grants and nonfinancial support from MedImmune, and grants from Regeneron and Novavax. C. G. G. reports serving as a consultant for Pfizer. R. G. W. reports grants from the CDC, funds to conduct clinical research from BioMerieux and Vertex Pharmaceuticals, and personal fees from BioMerieux and Visterra Inc. D. J. W. reports grants from the CDC. K. M. E. reports serving on a data and safety monitoring board for Novartis for which her institution receives fees. W. H. S. reports grants from the CDC and personal fees from BioFire Diagnostics, Venaxis, Abbott Point of Care and Cempra Pharmaceuticals. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. HHS Public Access Author manuscript J Infect Dis. Author manuscript; available in PMC 2017 December 11. Published in final edited form as: J Infect Dis. 2017 November 27; 216(9): 1104–1111. doi:10.1093/infdis/jix455. A uhor M anscript